Who bought PTLA?

Who bought PTLA?

(NASDAQ: ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA). The acquisition adds Factor Xa inhibitor reversal agent Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya® in Europe, to Alexion’s commercial portfolio.

Is Alexion Pharmaceuticals a good buy?

Alexion Pharmaceuticals has received a consensus rating of Hold. The company’s average rating score is 2.27, and is based on 4 buy ratings,ngs, and no sell ratings.

Is Alexion a good company to work for?

Alexion is a great place to work and really focused on the patients needs. The Mission and Culture inspires all levels and areas of the company engaging employees on its continuous growth. Jobs at Alexion Pharmaceuticals,Inc. Great company, cutting edge.

Who makes eculizumab?

Alexion started selling Soliris in 2008, making $295 million in 2007 with its stock price rising to 130% in 2010.

How much does Soliris cost?

The cost for Soliris intravenous solution (10 mg/mL) is around $6,820 for a supply of 30 milliliters, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.

Where is Alexion Pharmaceuticals located?

Boston

What drugs do Alexion make?

Alexion Pharmaceuticals, Inc. Boston, Massachusetts, U.S. Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH).

Where is Soliris manufactured?

Rhode Island manufacturing facility

When was Alexion founded?

1992, New Haven, CT

When was Ultomiris approved?

Development Timeline for Ultomiris

Date	Article
Oct 18, 2019	Approval Alexion Receives FDA Approval for Ultomiris (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (AHUS)
Dec 21, 2018	Approval FDA Approves Ultomiris (ravulizumab-cwvz) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Does Soliris cause weight gain?

Weight gain of 5 pounds in one week (fluid retention) Swelling of your legs, ankles, and/or feet. Pain or burning when you pass urine.

Can Soliris be administered at home?

NOTE:The first or initial Soliris dose must be administered in a medical facility for patients who are new to therapy. After that, subsequent doses can be home infused.

How is Soliris administered?

Only administer as an intravenous infusion. Do not administer as an intravenous push or bolus injection. Administer the Soliris admixture by intravenous infusion over 35 minutes in adults and 1 to 4 hours in pediatric patients via gravity feed, a syringe-type pump, or an infusion Page 7 7 pump.

How long does it take for Soliris to work?

Your doctor will discuss the ongoing timeline with you. How long will it take to see improvement after starting on Soliris? Some patients who responded to Soliris experienced improved gMG symptoms, usually by 12 weeks of starting treatment.

What are the side effects of Soliris?

Common side effects of Soliris include:

• headache,
• tiredness,
• nausea,
• vomiting,
• diarrhea,
• muscle pain,
• back pain, or.
• cold symptoms such as stuffy nose, sneezing, or sore throat.

How often is Soliris administered?

For patients with generalized Myasthenia Gravis, Soliris therapy consists of: • 900 mg weekly for the first 4 weeks, followed by • 1200 mg for the fifth doser, then • 1200 mg every 2 weeks thereafter. Administer Soliris at the recommended dosage regimen time points, or within two days of these time points.

How long is a Soliris infusion?

Soliris is given as an infusion into a vein. A healthcare provider will give you this injection. The infusion can take at least 35 minutes to complete in adults, or up to 4 hours in children.

Is eculizumab a chemo drug?

Eculizumab is the generic name for the trade chemotherapy drug Soliris. In some cases, health care professionals may use the trade name Soliris when referring to the generic drug name eculizumab.

Is aHUS an autoimmune disease?

Most cases of aHUS are genetic, although some may be acquired due to autoantibodies or occur for unknown reasons (idiopathic). aHUS may become chronic, and affected individuals may experience repeated episodes of the disorder.

How long can you live with aHUS?

In more than half of all patients, aHUS progresses to kidney failure, often within three years of diagnosis. Death rates among aHUS patients are as high as 25%.

Who treats aHUS?

Living with aHUS When you have aHUS, you should work with a nephrologist (a kidney doctor), and/or a hematologist (a blood doctor) to monitor your condition. You will need to have regular blood tests to check the health of your kidneys and your platelet and red blood cell counts.

How is aHUS diagnosed?

The first step in diagnosing aHUS is to recognize TMA: schistocytes, elevated lactate dehydrogenase (typically > 600 IU/L), decreased haptoglobin, decreased hemoglobin, and thrombocytopenia (platelet count less than 150,000 or > 25% decrease from baseline).

Is Hus rare?

Typical hemolytic uremic syndrome (HUS) is an uncommon disease that occurs in 5 to 15 percent of individuals, especially children, who are infected by the Escherichia coli (E. coli) bacterium, usually O157:H 0104:H4.

Can HUS be cured?

Most commonly, HUS is due to STEC infection. This can be a severe, life-threatening disease but in most cases is self-limiting and will resolve completely.

What diseases can cause kidney failure?

In the United States the two leading causes of kidney failure, also called end stage kidney disease or ESRD, are diabetes (also called Type 2, or adult onset diabetes) and high blood pressure. When these two diseases are controlled by treatment, the associated kidney disease can often be prevented or slowed down.